Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 5, 2020The AEGIS-II trial is evaluating the efficacy and safety of CSL112 (apolipoprotein A-1 [human]) during the high-risk 90-day period following a heart attack
KING OF PRUSSIA, Pa. 05 Nov 2020 Global biotherapeutics leader CSL Behring today announced that the study design manuscript for its landmark AEGIS-II (ApoA-I Event reducinG in Ischemic Syndromes...
-
Nov 3, 2020
Companies have completed the EU regulatory application for marketing approval of avacopan Regulatory submission based on positive data from the pivotal phase-III ADVOCATE trial of avacopan St...
-
Nov 2, 2020• Both US and European regulators grant special designation
KING OF PRUSSIA, Pa. 02 Nov 2020 Global biotherapeutics leader CSL Behring announced today that its investigational, plasma-derived hemopexin therapy (CSL889) received orphan drug designation from...
-
Oct 29, 2020
Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year 29 Oct 2020 Forbes magazine has named global biotechnology leader CSL Limited to its World’s Best Employers 2020 list. It...
-
Oct 29, 2020- Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year
KING OF PRUSSIA, Pa. 29 Oct 2020 Forbes magazine has named global biotechnology leader CSL Limited (parent company of CSL Behring) to its World’s Best Employers 2020 list. It is the fourth year...